Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 99, Issue , 2016, Pages 31-37

  Cappuzzo, Federico ^a   Morabito, Alessandro ^b   Normanno, Nicola ^b   Bidoli, Paolo ^c   Del Conte, Alessandro ^d   Giannetta, Laura ^e   Montanino, Agnese ^b   Mazzoni, Francesca ^f   Buosi, Roberta ^g   Burgio, Marco Angelo ^h   Cerea, Giulio ^e   Chiari, Rita ⁱ   Cortinovis, Diego ^c   Finocchiaro, Giovanna ^j   Foltran, Luisa ^d   Migliorino, Maria Rita ^k   Tiseo, Marcello ^l   Ferrari, Silvia ^m   De Marinis, Filippo ^k,n  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d Oncologia Medial A   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^j HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^l UNIVERSITY HOSPITAL OF PARMA   (Italy)

^m ASTRAZENECA   (United Kingdom)

ⁿ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

more..

Author keywords

Advanced stage NSCLC; EGFR mutation; Gefitinib; Rechallenge

Indexed keywords

CARBOPLATIN; CISPLATIN; GEFITINIB; GEMCITABINE; PEMETREXED; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FEMALE; FEVER; HEART INFARCTION; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; PARONYCHIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QUALITY OF LIFE; RASH; RETROSPECTIVE STUDY; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION; ADULT; CLINICAL TRIAL; DISEASE EXACERBATION; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT; TREATMENT OUTCOME;

EID: 84975833283     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.06.008     Document Type: Article

References (51)

1. [1] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386, 10.1002/ijc.29210.
2. [2] Browse the SEER Cancer Statistics Review 1975–2012, (n.d.). http://seer.cancer.gov/csr/1975_2012/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.14.html (accessed 4.11.15).
3. [3] Stinchcombe, T.E., Novel agents in development for advanced non-small cell lung cancer. Ther. Adv. Med. Oncol. 6 (2014), 240–253, 10.1177/1758834014532510.
4. [4] Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22 (2004), 2184–2191, 10.1200/JCO.2004.11.022.
5. [5] Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26 (2008), 3543–3551, 10.1200/JCO.2007.15.0375.
6. [6] Janku, F., Stewart, D.J., Kurzrock, R., Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nat. Rev. Clin. Oncol. 7 (2010), 401–414, 10.1038/nrclinonc.2010.64.
7. [7] Brabender, J., Danenberg, K.D., Metzger, R., Schneider, P.M., Park, J., Salonga, D., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. 7 (2001), 1850–1855.
8. [8] Hirsch, F.R., Varella-Garcia, M., Bunn, P.A., Di Maria, M.V., Veve, R., Bremmes, R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21 (2003), 3798–3807, 10.1200/JCO.2003.11.069.
9. [9] Mok, T.S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009), 947–957, 10.1056/NEJMoa0810699.
10. [10] Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362 (2010), 2380–2388, 10.1056/NEJMoa0909530.
11. [11] Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11 (2010), 121–128, 10.1016/S1470-2045(09)70364-X.
12. [12] Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005), 1527–1537, 10.1016/S0140-6736(05)67625-8.
13. [13] Jackman, D., Pao, W., Riely, G.J., Engelman, J.A., Kris, M.G., Jänne, P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer. J. Clin. Oncol. 28 (2010), 357–360, 10.1200/JCO.2009.24.7049.
14. [14] Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 20932–20937, 10.1073/pnas.0710370104.
15. [15] Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043, 10.1126/science.1141478.
16. [16] Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2, 2005, e73, 10.1371/journal.pmed.0020073.
17. [17] Oxnard, G.R., Arcila, M.E., Chmielecki, J., Ladanyi, M., Miller, V.A., Pao, W., New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin. Cancer Res. 17 (2011), 5530–5537, 10.1158/1078-0432.CCR-10-2571.
18. [18] Majem, M., Remon, J., Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Transl. Lung Cancer Res. 2 (2013), 226–237, 10.3978/j.issn.2218-6751.2013.03.09.
19. [19] Stewart, E.L., Tan, S.Z., Liu, G., Tsao, M.-S., Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl. Lung Cancer Res. 4 (2015), 67–81, 10.3978/j.issn.2218-6751.2014.11.06.
20. [20] Niederst, M.J., Sequist, L.V., Poirier, J.T., Mermel, C.H., Lockerman, E.L., Garcia, A.R., et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun., 6, 2015, 6377, 10.1038/ncomms7377.
21. [21] Inukai, M., Toyooka, S., Ito, S., Asano, H., Ichihara, S., Soh, J., et al. Presence of epidermal growth factor receptor gene T790 M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66 (2006), 7854–7858, 10.1158/0008-5472.CAN-06-1951.
22. [22] Kim, D.-W., O10. 2HM61713, an EGFR-mutant selective inhibitor. Ann. Oncol., 26(Suppl. 2), 2015, ii14, 10.1093/annonc/mdv088.2.
23. [23] Sequist, L.V., Soria, J.-C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709, 10.1056/NEJMoa1413654.
24. [24] Jänne, P.A., Yang, J.C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S.S., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699, 10.1056/NEJMoa1411817.
25. [25] Chaft, J.E., Oxnard, G.R., Sima, C.S., Kris, M.G., Miller, V.A., Riely, G.J., Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res. 17 (2011), 6298–6303, 10.1158/1078-0432.CCR-11-1468.
26. [26] Riely, G.J., Kris, M.G., Zhao, B., Akhurst, T., Milton, D.T., Moore, E., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin. Cancer Res. 13 (2007), 5150–5155, 10.1158/1078-0432.CCR-07-0560.
27. [27] Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med., 3, 2011, 75ra26, 10.1126/scitranslmed.3002003.
28. [28] Sharma, S.V., Lee, D.Y., Li, B., Quinlan, M.P., Takahashi, F., Maheswaran, S., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 (2010), 69–80, 10.1016/j.cell.2010.02.027.
29. [29] Yokouchi, H., Yamazaki, K., Kinoshita, I., Konishi, J., Asahina, H., Sukoh, N., et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer, 7, 2007, 51, 10.1186/1471-2407-7-51.
30. [30] Becker, A., Crombag, L., Heideman, D.A.M., Thunnissen, F.B., van Wijk, A.W., Postmus, P.E., et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47 (2011), 2603–2606, 10.1016/j.ejca.2011.06.046.
31. [31] Tseng, J.-S., Yang, T.-Y., Chen, K.-C., Hsu, K.-H., Yu, C.-J., Liao, W.-Y., et al. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. Onco Targets Ther. 7 (2014), 799–805, 10.2147/OTT.S62639.
32. [32] Zeng, Z., Yan, H., Zhang, X., Zhong, W., He, Y., Guan, J., et al. Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor. Lung Cancer 86 (2014), 219–224, 10.1016/j.lungcan.2014.09.008.
33. [33] Park, S., Keam, B., Kim, S.H., Kim, K.H., Kim, Y.J., Kim, J.-S., et al. Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor failure in non-small cell lung cancer patients with EGFR mutations. Cancer Res. Treat., 2015, 10.4143/crt.2014.244.
34. [34] Asahina, H., Oizumi, S., Inoue, A., Kinoshita, I., Ishida, T., Fujita, Y., et al. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 79 (2010), 423–429, 10.1159/000326488.
35. [35] Koizumi, T., Agatsuma, T., Ikegami, K., Suzuki, T., Kobayashi, T., Kanda, S., et al. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Clin. Lung Cancer 13 (2012), 458–463, 10.1016/j.cllc.2012.01.006.
36. [36] Oh, I.-J., Ban, H.-J., Kim, K.-S., Kim, Y.-C., Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 77 (2012), 121–127, 10.1016/j.lungcan.2012.01.012.
37. [37] Tomizawa, Y., Fujita, Y., Tamura, A., Shirai, M., Shibata, S., Kawabata, T., et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 68 (2010), 269–272, 10.1016/j.lungcan.2009.06.025.
38. [38] Xia, G.-H., Zeng, Y., Fang, Y., Yu, S.-R., Wang, L., Shi, M.-Q., et al. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI. Cancer Biol. Med. 11 (2014), 270–276, 10.7497/j.issn.2095-3941.2014.04.006.
39. [39] Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment. Cancer 47 (1981), 207–214.
40. [40] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45 (2009), 228–247, 10.1016/j.ejca.2008.10.026.
41. [41] Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 11 (1993), 570–579.
42. [42] Cella, D.F., Bonomi, A.E., Lloyd, S.R., Tulsky, D.S., Kaplan, E., Bonomi, P., Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer 12 (1995), 199–220.
43. [43] Fleiss, J.L., Statistical methods for rates and proportions. second edition, 1981, Wiley, John and Sons, Incorporated, New York, N.Y.
44. [44] Tang, C., Gao, H., Li, X., Liu, Y., Li, J., Qin, H., et al. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer. J. Cancer Res. Clin. Oncol. 140 (2014), 427–433, 10.1007/s00432-014-1582-x.
45. [45] Miller, V.A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13 (2012), 528–538, 10.1016/S1470-2045(12)70087-6.
46. [46] Landi, L., Tiseo, M., Chiari, R., Ricciardi, S., Rossi, E., Galetta, D., et al. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Clin. Lung Cancer, 15, 2014, 10.1016/j.cllc.2014.07.002 411–417e4.
47. [47] Weaver, Z., Difilippantonio, S., Carretero, J., Martin, P.L., El Meskini, R., Iacovelli, A.J., et al. Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response. Cancer Res. 72 (2012), 5921–5933, 10.1158/0008-5472.CAN-12-0736.
48. [48] He, C., Zheng, L., Xu, Y., Liu, M., Li, Y., Xu, J., Highly sensitive and noninvasive detection of epidermal growth factor receptor T790 M mutation in non-small cell lung cancer. Clin. Chim. Acta Int. J. Clin. Chem. 425 (2013), 119–124, 10.1016/j.cca.2013.07.012.
49. [49] Wang, Z., Chen, R., Wang, S., Zhong, J., Wu, M., Zhao, J., et al. Quantification and dynamic monitoring of EGFR T790 M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One, 9, 2014, e110780, 10.1371/journal.pone.0110780.
50. [50] Thress, K.S., Brant, R., Carr, T.H., Dearden, S., Jenkins, S., Brown, H., et al. EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer, 2015, 10.1016/j.lungcan.2015.10.004.
51. [51] Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)., J. Clin. Oncol. (n.d.). http://meetinglibrary.asco.org/content/154634-156 (accessed 22.07.15).